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Lupus anticoagulant-hypoprothrombinemia 
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Department  of  Internal  Medicine,  College  of  Medicine  Chosun  University,  Gwangju,  Korea 
The  presence  of  lupus  anticoagulant  is  associated  with  an  elevated  risk  of  venous  and  arterial  thrombosis,  and 
recurrent  miscarriages  as  well.  For  some  cases,  this  disease  can  present  with  bleeding  as  a  consequence  of  lupus 
anticoagulant‐hypoprothrombinemia (LAHPS). LAHPS is a rare disease and it is reported to be most frequent in young 
females with/without systemic lupus erythematosus or in healthy children who are suffering with a viral infection. In such 
cases,  steroid  therapy  is  usually  effective  in  normalizing  the  biological  abnormalities  and  controlling  the  bleeding 
problems. 
A 34-year-old previously healthy man was admitted to our department because of his prolonged coagulation times; 
these  abnormalities  were  discovered  before  performing  orthopedic  surgery.  The  prothrombin  time  (PT)  was  15.2  sec, 
and the activated partial thromboplastin time (APTT) was 37.7 sec. A 1:1 dilution of patient plasma with normal plasma 
nearly corrected the PT, but this failed to correct the APTT. Evaluation of the clotting factors revealed decreased levels 
of factors II, V, VIII, IX and XI. The presence of LA was demonstrated by the dRVVT test, and the patient was diagnosed 
with  LAHPS.  He  was  successfully  treated  with  corticosteroid  before  performing  the  orthopedic  surgery.
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INTRODUCTION
The most common clinical presentation of patients with lupus 
anticoagulant  antibody  is  arterial  or  venous  thromboembolism
1). 
Hemorrhage is much less common and this is usually attributable 
to  the  associated  thrombocytopenia,  a  platelet  dysfunction,  a 
prothrombin  deficiency  or  other  underlying  coagulopathies
2, 3). 
Lupus  anticoagulant‐hypoprothrombinemia  (LAHPS)  is  a  rare 
syndrome. In many cases, steroid is required to treat patients’ 
h e m o r r h a g e s ,  a n d  s t e r o i d  h a s  b e e n  n o t e d  t o  p r o m p t l y  c o r r e c t  
the  hypoprothrombinemia  and  control  bleeding  events
4). 
H e r e i n ,  w e  r e p o r t  o n  a  3 4 - y e a r - o l d  p r e v i o u s l y  h e a l t h y  m a n  
with  LAHPS.  He  was  referred  to  our  hospital  because  of  his 
prolonged coagulation time, which was discovered during his lab 
work‐up  for  an  orthopedic  operation.  The  laboratory  studies 
showed  LAHPS  with  microscopic  hematuria;  however,  any  viral 
infection  or  other  systemic  disease  was  not  found.  He  was 
successfully  treated  with  corticosteroid  before  undergoing 
orthopedic  surgery. 
CASE REPORT
A  34-year-old-man  was  admitted  to  another  hospital  for  an 
orthopedic  operation.  The  coagulation  studies  showed  a 
prolonged  prothrombin  time  (PT)  and  an  activated  partial 
thromboplastin  time  (APTT).  He  was  treated  with  fresh  frozen 
plasma,  but  without  success.  After  2  weeks,  the  patient  was 
referred to our hospital. He was not taking any medication, and 
especially, any anticoagulant and antiplatelet agents. He had no 
personal or family history of any bleeding disorder. The physical 
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PT  (sec)
APTT  (sec)
Factor  II  (%)
F a c t o r  V  ( % )
Factor  VII  (%)
F a c t o r  V I I I  ( % )
Factor  IX  (%)
Factor  X  (%)
Factor  XI  (%)
F a c t o r  X I I  ( % )
Prednisone  (mg/day)
15.2
37.7
29
24
82
3.4
5.8
1.2
-
12.2
26.9
67
62
113
49
51
104
31
108
60
10.7
23.2
40
10.9
23.5
92
81
114
81
103
98
78
91
30
12.5
28.6
-
The  date  of  administering  prednisone:  8  Dec  04
Table  1.  Results  of  the  Serial  Coagulation  Studies  and  the  Treatment
rupture. The initial laboratory tests showed a leukocyte count of 
8,200/mm
3, a hemoglobin of 14.7 g/dL and a platelet count of 
226,000/mm
3. The PT was 15.2 sec (normal values (NV): 10.0- 
13.0 sec), the APTT was 37.7sec (NV: 27.5-34.7 sec). Evaluation 
of the clotting factors revealed decreased levels of factors II, V, 
V I I I ,  I X  a n d  X I  ( T a b l e  1 ) .  A  1 : 1  d i l u t i o n  o f  p a t i e n t  p l a s m a  w i t h 
normal plasma nearly corrected the PT, but this failed to correct 
the  APTT.  The  diluted  Russell’s  viper  venom  time  (dRVVT, 
American  Diagnostica,)  was  positive.  The  anticardiolipin 
antibodies  IgG  and  IgM  were  positive.  The  tests  for  antinuclear 
antibodies  and  anti‐double  stranded  DNA  antibodies  were 
negative;  the  C3  and  C4  complement  levels  were  low.  The 
patient denied any symptoms that would be suggestive of SLE, 
and there was no family history of bleeding or connective tissue 
disease.  An  extensive  infectious  disease  workup  ruled  out 
h e p a t i t i s  A ,  B  a n d  C ,  c y t o m e g a l o v i r u s  a n d  E p s t e i n ‐Barr  virus. 
Finally, we diagnosed the patient as having lupus anticoagulant- 
hypoprothrombinemia  (LAHPS).  However,  he  displayed  only 
microscopic  hematuria  and  he  was  without  SLE  or  any 
underlying  disease.  So,  we  closely  followed  the  patient’s 
laboratory  findings  and  clinical  symptoms  for  2  months.  He  did 
not show any symptoms or signs of bleeding, yet the abnormal 
laboratory  findings  were  sustained.  We  decided  to  try 
corticosteroid  treatment  to  prepare  the  patient  for  orthopedic 
surgery  and  then  2  weeks  later,  the  coagulation  studies  were 
significantly  improved.  He  successfully  underwent  the  operation 
and  was  discharged.  At  present,  he  hasn’t  any  symptoms  or 
signs  of  thrombosis,  hemorrhage  and  SLE. 
DISCUSSION
Lupus anticoagulant (LA) is an antiphospholipid antibody that 
causes  prolonged  in  vitro  coagulation  times.  This  may  be 
associated  with  a  hypercoagulable  state  together  with  throm-
boembolic  events
1).  A  bleeding  diathesis  is  a  rare  manifestation 
of lupus anticoagulant, and when it occurs, it was nearly always 
due  to  thrombocytopenia  or  Factor  II  deficiency
2, 3). 
Lupus anticoagulant‐hypoprothrombinemia syndrome (LAHPS) is 
a  rare  clinical  malady  that  can  occur  in  association  with  SLE, 
transient  viral  infections,  drug  reactions  or  even  in  healthy 
individuals
5, 6). It mostly occurs in young females, and only rarely 
in  those  adults  who  are  without  systemic  lupus  erythematosus, 
an  underlying  disease  or  a  preceding  illness
2). 
The clinical findings are generally asymptomatic, but there can 
be  severe  hemorrhagic  symptoms  such  as  brain  hemorrhage, 
gastrointestinal  bleeding  and  diffuse  muscular  hemorrhage. 
These patients may present with severe life threatening bleeding 
diathesis  if  the  Factor  II  level  is  very  low  (i.e.,  usually  under 
10%)
2).  I n  o u r  c a s e ,  t h e  F a c t o r  I I  l e v e l  w a s  2 9 %  a n d  o n l y  
microscopic  hematuria  was  observed.
Simel et al. have reported on a case of LAHPS for which the 
patient did not respond to replacement therapy, and the patient 
showed  a  significant  response  to  immunosuppressive  drugs
7). 
Most  of  the  cases  previously  reported  in  the  literature  have 
responded  well  to  administering  only  prednisone  treatment
4).  A 
few  cases  needed  an  additional  immunosuppressive  drug  such 
as  cyclophosphamide  or  azathioprine
7, 8).  Corticosteroid  therapy 
is  the  treatment  of  choice  for  LAHPS  associated  with  SLE;  it 
normalizes the abnormal coagulation times, including the PT, the 
APTT  and  the  clotting factors. For those  cases associated with 
viral infection, the LAHPS spontaneously reverses itself when the 
infection  has  been  resolved,  and  so  steroid  therapy  is  not 
necessary.  Our  patient  had  only  microscopic  hematuria  without 
S L E  o r  a n y  u n d e r l y i n g  d i e s e s e .  T h e r e f o r e ,  w e  f o l l o w e d  u p  t h e  
laboratory  findings  and  clinical  symptoms  for  2  months;  during 
this  time,  he  did  not  display  any  symptoms  and  signs  of 
bleeding.  However,  the  abnormal  laboratory  findings  were 
sustained.  We  decided  to  institute  corticosteroid  treatment  for 
getting  him  ready  for  orthopedic  surgery;  2  weeks  later,  the 
coagulation  studies  were  significantly  improved.  He  successfully 
received the operation and was discharged. At present, he has Choon  Hae  Chung,  et  al:  LAHPS  in  healthy  adult 151
no  signs  or  symptoms  of  thrombosis,  hemorrhage  and  SLE. 
Prompt, close follow up of these patients is crucial because they 
may develop, at any time, the full clinical syndrome of SLE and 
thrombosis  because  of  the  presence  of  LA.
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